Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 35 Researches
7.6
USERS' SCORE
Good
Based on 5 Reviews
8.3
Supplement Facts
Serving Size: 2 Softgels
Serving Per Container: 60
Amount Per Serving
%DV
Calories
25
Total Fat
2.5 g
3%**
Total Fish Oil
2,600 mg
†
EPA (Eicosapentaenoic acid) Omega-3
750 mg
†
DHA (Docosahexaenoic acid) Omega-3
750 mg
†
DPA (Docosapentaenoic acid) Omega-3
150 mg
†
Top Medical Research Studies
9
We explored the impact of eicosapentaenoic acid (EPA), a nutrient known for its heart benefits, on diabetic cardiomyopathy (DC), a condition leading to heart failure. Our study focused on diabetic mice and revealed that EPA plays a protective role against DC, particularly by reducing harmful M1-polarized macrophages in the heart.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
Read More
9
We explored the effects of docosapentaenoic acid (DPAn-6), an omega-6 essential fatty acid, on cardiovascular disease, particularly how it influences platelet reactivity and blood clot formation. Our study involved treatments using human and mouse blood, as well as isolated platelets, to evaluate whether DPAn-6 and its oxidized metabolites could inhibit platelet activation directly.
We observed that DPAn-6 levels increased in platelets after fatty acid supplementation. Notably, it exhibited a strong ability to inhibit platelet activation through its oxidized forms, which are produced by a specific enzyme known as 12-lipoxygenase. Additionally, we found that these inhibitory effects were reversed when we blocked the action of the PPARα nuclear receptor, indicating that the way DPAn-6 works is closely tied to this receptor.
By administering DPAn-6 or its oxidized derivatives to mice, we noted a significant reduction in clot formation following vessel injury. However, this effect was absent in mice lacking PPARα, further confirming the importance of this receptor in mediating the effects of DPAn-6. Collectively, our findings suggest that docosapentaenoic acid and its derivatives could be beneficial in reducing the risk of thrombosis, pointing towards potential new strategies to tackle thrombotic-related diseases through PPARα targeting.
We observed that DPAn-6 levels increased in platelets after fatty acid supplementation. Notably, it exhibited a strong ability to inhibit platelet activation through its oxidized forms, which are produced by a specific enzyme known as 12-lipoxygenase. Additionally, we found that these inhibitory effects were reversed when we blocked the action of the PPARα nuclear receptor, indicating that the way DPAn-6 works is closely tied to this receptor.
By administering DPAn-6 or its oxidized derivatives to mice, we noted a significant reduction in clot formation following vessel injury. However, this effect was absent in mice lacking PPARα, further confirming the importance of this receptor in mediating the effects of DPAn-6. Collectively, our findings suggest that docosapentaenoic acid and its derivatives could be beneficial in reducing the risk of thrombosis, pointing towards potential new strategies to tackle thrombotic-related diseases through PPARα targeting.
Read More
8
We explored how eicosapentaenoic acid (EPA), a key component of omega-3 fatty acids, influences cardiovascular health by analyzing the Vitamin D and Omega-3 Trial (VITAL). This large, randomized controlled trial involved 25,871 older adults in the U.S., with a median follow-up of 5.3 years to assess the effects of daily supplementation.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
Read More
Most Useful Reviews
9
Cardiovascular health support
Great! The quality of ingredients is impressive. Sourced from high-quality fish, this omega-3 supplement is effective for cardiovascular disease and overall wellness. Regular consumption helps reduce inflammation and supports joint health while being easy to swallow.
Read More
7.5
Skin condition improved
5 people found this helpful
Very well. Of almost all omega-3 preparations, I appreciated the high content of polyunsaturated fatty acids in one capsule. My family and I take omega-3 consistently to improve vision, the cardiovascular disease, boost immunity, and regulate cholesterol. After two weeks, the condition of my skin improved significantly, particularly on my elbows, knees, and heels.
Read More
7.5
Joint support noted
Great fish oil supplement! High quality and dosage of EPA, DHA, and even DPA omega-3 fats. It's fantastic for joints and also supports cardiovascular disease.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 35 Researches
7.6
- All Researches
9
Icosapent ethyl reduces cardiovascular risks
We explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing cardiovascular events among statin-treated patients who had high cardiovascular risk and controlled cholesterol levels.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
Read More
9
We explored the effectiveness of eicosapentaenoic acid (EPA), a type of omega-3 polyunsaturated fatty acid (PUFA), in managing heart failure. By analyzing data from multiple randomized controlled trials, we aimed to identify the best doses and treatment durations for EPA supplementation.
The findings from our network meta-analysis included 14 studies with nearly 9,000 participants, primarily older adults with heart failure. We discovered that high doses of omega-3 PUFAs, specifically between 2000 and 4000 mg per day for at least one year, significantly improved heart function. This was measured by an increase in the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter supplementation periods did not yield similar benefits. It's worth noting that EPA supplementation did not increase the risk of adverse events, as dropout rates and overall mortality were comparable to control groups.
Our study suggests that long-term, high-dose omega-3 supplementation shows promise for enhancing heart function in individuals with heart failure. Nonetheless, we believe that more in-depth clinical trials are necessary to confirm these results and ensure the findings are robust and reliable.
The findings from our network meta-analysis included 14 studies with nearly 9,000 participants, primarily older adults with heart failure. We discovered that high doses of omega-3 PUFAs, specifically between 2000 and 4000 mg per day for at least one year, significantly improved heart function. This was measured by an increase in the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter supplementation periods did not yield similar benefits. It's worth noting that EPA supplementation did not increase the risk of adverse events, as dropout rates and overall mortality were comparable to control groups.
Our study suggests that long-term, high-dose omega-3 supplementation shows promise for enhancing heart function in individuals with heart failure. Nonetheless, we believe that more in-depth clinical trials are necessary to confirm these results and ensure the findings are robust and reliable.
Read More
9
We delved into how Antarctic krill oil, rich in eicosapentaenoic acid (EPA), can influence cardiovascular health, specifically in the context of obesity. Our focus centered on its effects in mice fed a high-fat diet, which typically leads to increased cholesterol levels and oxidative stress—conditions that can heighten cardiovascular disease risk.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Read More
9
We explored the impact of eicosapentaenoic acid (EPA), a nutrient known for its heart benefits, on diabetic cardiomyopathy (DC), a condition leading to heart failure. Our study focused on diabetic mice and revealed that EPA plays a protective role against DC, particularly by reducing harmful M1-polarized macrophages in the heart.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
Read More
9
We explored the impact of docosapentaenoic acid (DPA) on cardiovascular disease mortality among patients with cardiometabolic disease. This comprehensive study analyzed data from over 8,500 participants, focusing on the effects of specific dietary fats on overall health outcomes over a median follow-up period of 10.3 years.
Our findings indicate that higher consumption of DPA is associated with a significant reduction in cardiovascular deaths. In fact, patients who consumed more DPA had a 36% lower risk of dying from cardiovascular disease compared to those who consumed the least. This suggests that adding DPA-rich foods to our diets could play a critical role in improving heart health for those with cardiometabolic conditions.
Furthermore, we noted that the beneficial effects of DPA could be influenced by key cholesterol levels, such as total cholesterol and triglycerides. This means that DPA intake might help lower cardiovascular mortality through its positive impact on these important health markers.
Overall, our results highlight the potential of DPA in promoting cardiovascular health. We emphasize the importance of further research to confirm these findings and encourage a balanced diet that includes beneficial fatty acids like DPA.
Our findings indicate that higher consumption of DPA is associated with a significant reduction in cardiovascular deaths. In fact, patients who consumed more DPA had a 36% lower risk of dying from cardiovascular disease compared to those who consumed the least. This suggests that adding DPA-rich foods to our diets could play a critical role in improving heart health for those with cardiometabolic conditions.
Furthermore, we noted that the beneficial effects of DPA could be influenced by key cholesterol levels, such as total cholesterol and triglycerides. This means that DPA intake might help lower cardiovascular mortality through its positive impact on these important health markers.
Overall, our results highlight the potential of DPA in promoting cardiovascular health. We emphasize the importance of further research to confirm these findings and encourage a balanced diet that includes beneficial fatty acids like DPA.
Read More
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
9
Cardiovascular health support
Great! The quality of ingredients is impressive. Sourced from high-quality fish, this omega-3 supplement is effective for cardiovascular disease and overall wellness. Regular consumption helps reduce inflammation and supports joint health while being easy to swallow.
Read More
7.5
Skin condition improved
5 people found this helpful
Very well. Of almost all omega-3 preparations, I appreciated the high content of polyunsaturated fatty acids in one capsule. My family and I take omega-3 consistently to improve vision, the cardiovascular disease, boost immunity, and regulate cholesterol. After two weeks, the condition of my skin improved significantly, particularly on my elbows, knees, and heels.
Read More
7.5
Joint support noted
Great fish oil supplement! High quality and dosage of EPA, DHA, and even DPA omega-3 fats. It's fantastic for joints and also supports cardiovascular disease.
Read More
7.5
Boosts immunity effectively
An excellent preparation for immunity and cardiovascular disease. I take it with my family regularly.
Read More
7.5
Cardiovascular benefits observed
Great product. It significantly improves the cardiovascular disease.
Read More
Frequently Asked Questions
7.5
Skin condition improved
5 people found this helpful
Very well. Of almost all omega-3 preparations, I appreciated the high content of polyunsaturated fatty acids in one capsule. My family and I take omega-3 consistently to improve vision, the cardiovascular disease, boost immunity, and regulate cholesterol. After two weeks, the condition of my skin improved significantly, particularly on my elbows, knees, and heels.
7.5
Boosts immunity effectively
An excellent preparation for immunity and cardiovascular disease. I take it with my family regularly.
9
Cardiovascular health support
Great! The quality of ingredients is impressive. Sourced from high-quality fish, this omega-3 supplement is effective for cardiovascular disease and overall wellness. Regular consumption helps reduce inflammation and supports joint health while being easy to swallow.
7.5
Cardiovascular benefits observed
Great product. It significantly improves the cardiovascular disease.
8
We explored how eicosapentaenoic acid (EPA), a key component of omega-3 fatty acids, influences cardiovascular health by analyzing the Vitamin D and Omega-3 Trial (VITAL). This large, randomized controlled trial involved 25,871 older adults in the U.S., with a median follow-up of 5.3 years to assess the effects of daily supplementation.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
7
Omega-3s Reduce Heart Disease Risk
We explored how levels of marine omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), impact the risk of cardiovascular (CV) events and overall mortality in patients undergoing maintenance hemodialysis. This study involved a robust, prospective multicenter cohort design with five years of follow-up, focusing on how different levels of these beneficial fatty acids correlate with heart health.
Our findings revealed that patients with lower levels of these fatty acids faced a significantly higher risk of cardiovascular events, as well as an increase in peripheral arterial disease and all-cause mortality. Specifically, those in the lowest group of marine n-3 PUFA levels had a markedly elevated risk compared to those with higher levels.
This suggests that incorporating more sources of EPA and DHA into the diet or through supplements could be a valuable strategy for improving heart health among patients receiving hemodialysis. This study contributes to the growing body of evidence supporting the heart-protective benefits of omega-3 fatty acids, particularly in high-risk populations.
Our findings revealed that patients with lower levels of these fatty acids faced a significantly higher risk of cardiovascular events, as well as an increase in peripheral arterial disease and all-cause mortality. Specifically, those in the lowest group of marine n-3 PUFA levels had a markedly elevated risk compared to those with higher levels.
This suggests that incorporating more sources of EPA and DHA into the diet or through supplements could be a valuable strategy for improving heart health among patients receiving hemodialysis. This study contributes to the growing body of evidence supporting the heart-protective benefits of omega-3 fatty acids, particularly in high-risk populations.
9
Icosapent ethyl reduces cardiovascular risks
We explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing cardiovascular events among statin-treated patients who had high cardiovascular risk and controlled cholesterol levels.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
8
Eicosapentaenoic acid improves endothelial function
We aimed to explore how eicosapentaenoic acid (EPA) influences cardiovascular health, specifically its effects on endothelial function in patients dealing with coronary artery disease (CAD) while on statin therapy. Our study involved 150 patients who were receiving statins to lower their cholesterol levels and who had LDL cholesterol levels below 100 mg/dL.
By measuring serum omega-3 fatty acid levels, we assessed endothelial function using a technique called flow-mediated dilation (FMD) of the brachial artery. This method helps understand how well blood vessels are responding to blood flow. Among these patients, we identified 65 individuals with impaired FMD (less than 6%) who also had low EPA/arachidonic acid ratios. We then provided them with EPA therapy and reassessed their endothelial function after three months.
Our analysis revealed that higher levels of docosahexaenoic acid (DHA) and combined EPA plus DHA were linked to better FMD outcomes. Notably, after EPA treatment, the FMD percentage improved significantly from 3.7% to 4.1% among those with low EPA/AA ratios. This improvement was even more pronounced in patients who exhibited both low EPA/AA levels and high triglyceride levels.
In summary, our findings indicate that serum omega-3 fatty acids are connected to endothelial dysfunction in CAD patients on statin therapy. Moreover, EPA therapy shows promise in enhancing endothelial function, particularly in a subset of patients with specific biochemical profiles.
By measuring serum omega-3 fatty acid levels, we assessed endothelial function using a technique called flow-mediated dilation (FMD) of the brachial artery. This method helps understand how well blood vessels are responding to blood flow. Among these patients, we identified 65 individuals with impaired FMD (less than 6%) who also had low EPA/arachidonic acid ratios. We then provided them with EPA therapy and reassessed their endothelial function after three months.
Our analysis revealed that higher levels of docosahexaenoic acid (DHA) and combined EPA plus DHA were linked to better FMD outcomes. Notably, after EPA treatment, the FMD percentage improved significantly from 3.7% to 4.1% among those with low EPA/AA ratios. This improvement was even more pronounced in patients who exhibited both low EPA/AA levels and high triglyceride levels.
In summary, our findings indicate that serum omega-3 fatty acids are connected to endothelial dysfunction in CAD patients on statin therapy. Moreover, EPA therapy shows promise in enhancing endothelial function, particularly in a subset of patients with specific biochemical profiles.
References
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. 10.1016/j.ajcnut.2025.02.028
- Liboriussen C, Nygaard L, Jensen JD, Schmidt EB, Glerup RI, et al. Low Plasma Marine N-3 Polyunsaturated Fatty Acids are Associated with Increased Risk of Cardiovascular Events in Patients Treated with Maintenance Hemodialysis. J Ren Nutr. 2025. 10.1053/j.jrn.2025.02.001
- Yunoki K, Matsumi H, Miyoshi T, Kubo M, Hata Y, et al. Clinical Significance of Serum Omega-3 Fatty Acids on Endothelial Function in Patients with Coronary Artery Disease Under Statin Therapy. J Cardiovasc Dev Dis. 2025;12. 10.3390/jcdd12020060
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. 10.1161/JAHA.124.038656
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. 10.1016/j.advnut.2025.100366
- Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. 10.1007/s40261-024-01417-4
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. 10.3390/jcm14010026
- Lamon-Fava S. Associations between omega-3 fatty acid-derived lipid mediators and markers of inflammation in older subjects with low-grade chronic inflammation. Prostaglandins Other Lipid Mediat. 2025;176:106948. 10.1016/j.prostaglandins.2025.106948
- Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. 10.7759/cureus.73417
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. 10.1016/j.pcad.2024.11.003
- Choi JH, Park SE, Kim S. Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice. Nutrients. 2024;16. 10.3390/nu16213614
- So J, Yao JH, Magadmi R, Matthan NR, Lamon-Fava S. Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2024;203:102655. 10.1016/j.plefa.2024.102655
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. 10.1038/s44319-024-00271-x
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. 10.3389/fnut.2024.1423228
- Follonier C, Rabassa G, Branca M, Carballo D, Koskinas K, et al. Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes. Atheroscler Plus. 2024;58:1. 10.1016/j.athplu.2024.09.002
- Koutsaliaris IK, Pantazi D, Tsouka AN, Argyropoulou O, Tellis CC, et al. Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. Int J Mol Sci. 2024;25. 10.3390/ijms251810136
- Ren Y, Chen B, Zhang H, Xu S. A cohort study reveals shared and distinct serum metabolic biomarkers for major adverse cardiovascular events in middle-aged and older adults. Geroscience. 2025. 10.1007/s11357-025-01544-6
- Arghavani H, Bilodeau JF, Rudkowska I. Association Between Circulating Fatty Acids and Blood Pressure: A Review. Curr Nutr Rep. 2025;14:15. 10.1007/s13668-024-00602-3
- Li J, Guo J, Yuen M, Yuen H, Peng Q. The comparative effects of ω-7 fatty acid-rich sea buckthorn oil and ω-3 fatty acid-rich DHA algal oil on improving high-fat diet-induced hyperlipidemia. Food Funct. 2025;16:1241. 10.1039/d4fo04961f
- Berkowitz L, Echeverría G, Salazar C, Faúndez C, Coe CL, et al. Lipidomic Signature of Healthy Diet Adherence and Its Association with Cardiometabolic Risk in American Adults. Nutrients. 2024;16. 10.3390/nu16233995
- Shi F, Chowdhury R, Sofianopoulou E, Koulman A, Sun L, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025;32:233. 10.1093/eurjpc/zwae315
- Che J, He N, Kuang X, Zheng C, Zhou R, et al. Dietary n-3 Fatty Acids Intake and All-Cause and Cardiovascular Mortality in Patients With Prediabetes and Diabetes. J Clin Endocrinol Metab. 2024;109:2847. 10.1210/clinem/dgae265
- Reiner MF, Bertschi DA, Werlen L, Wiencierz A, Aeschbacher S, et al. Omega-3 Fatty Acids and Markers of Thrombosis in Patients with Atrial Fibrillation. Nutrients. 2024;16. 10.3390/nu16020178
- Zhao M, Xiao M, Tan Q, Ji J, Lu F. Association between dietary omega-3 intake and coronary heart disease among American adults: The NHANES, 1999-2018. PLoS One. 2023;18:e0294861. 10.1371/journal.pone.0294861
- Chen H, Leng X, Liu S, Zeng Z, Huang F, et al. Association between dietary intake of omega-3 polyunsaturated fatty acids and all-cause and cardiovascular mortality among hypertensive adults: Results from NHANES 1999-2018. Clin Nutr. 2023;42:2434. 10.1016/j.clnu.2023.09.011
- Yang T, Yi J, He Y, Zhang J, Li X, et al. Associations of Dietary Fats with All-Cause Mortality and Cardiovascular Disease Mortality among Patients with Cardiometabolic Disease. Nutrients. 2022;14. 10.3390/nu14173608
- Jiang H, Wang L, Wang D, Yan N, Li C, et al. Omega-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality. Clin Nutr. 2022;41:1798. 10.1016/j.clnu.2022.06.034
- Maki KC, Bays HE, Ballantyne CM, Underberg JA, Kastelein JJP, et al. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study. J Am Heart Assoc. 2022;11:e024176. 10.1161/JAHA.121.024176
- Heileson JL, Anzalone AJ, Carbuhn AF, Askow AT, Stone JD, et al. The effect of omega-3 fatty acids on a biomarker of head trauma in NCAA football athletes: a multi-site, non-randomized study. J Int Soc Sports Nutr. 2021;18:65. 10.1186/s12970-021-00461-1
- Xuan C, Tian QW, Li H, Guo JJ, He GW, et al. Serum fatty acids profile and association with early-onset coronary artery disease. Ther Adv Chronic Dis. 2021;12:20406223211033102. 10.1177/20406223211033102
- Zelniker TA, Morrow DA, Scirica BM, Furtado JD, Guo J, et al. Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. J Am Heart Assoc. 2021;10:e017401. 10.1161/JAHA.120.017401
- Harris WS, Leonard D, Radford NB, Barlow CE, Steele MR, et al. Increases in erythrocyte DHA are not associated with increases in LDL-cholesterol: Cooper center longitudinal study. J Clin Lipidol. 2021;15:212. 10.1016/j.jacl.2020.11.011
- Yeung J, Adili R, Yamaguchi A, Freedman CJ, Chen A, et al. Omega-6 DPA and its 12-lipoxygenase-oxidized lipids regulate platelet reactivity in a nongenomic PPARα-dependent manner. Blood Adv. 2020;4:4522. 10.1182/bloodadvances.2020002493
- Ding D, Zhong QW, Zuo LS, Ling CW, Xiong F, et al. Association between erythrocyte membrane n-3 and n-6 polyunsaturated fatty acids and carotid atherosclerosis: A prospective study. Atherosclerosis. 2020;298:7. 10.1016/j.atherosclerosis.2020.02.013
- Fosshaug LE, Colas RA, Anstensrud AK, Gregersen I, Nymo S, et al. Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction. EBioMedicine. 2019;46:264. 10.1016/j.ebiom.2019.07.024
